Inclusion Criteria:

   - Histologically confirmed advanced malignancy (solid tumor or lymphoma) that is
   metastatic or unresectable for which standard curative measures do not exist or are no
   longer effective

   - Eastern Cooperative Oncology Group (ECOG) performance status
   - Life expectancy greater than 3 months

   - Adequate organ and marrow function

   - Written informed consent

   - Use of acceptable methods of contraception during the course of the study and for 3
   months after completion of study

   - In the MTD expanded cohort: at least 20 subjects with metastatic and/or
   advanced/locally recurrent Medullary Thyroid Cancer not appropriate for surgical
   resection with measurable disease as defined by RECIST

Exclusion Criteria:

   - Chemotherapy, immunotherapy or radiation within 4 weeks (or nitrosoureas or mitomycin
   C within 6 weeks) before the first scheduled dose of XL184

   - Administration of an investigational drug within 30 days of the first dose of XL184

   - Subject has not recovered from adverse events due to investigational agents or other
   medications administered more than 4 weeks before study enrollment

   - Known brain metastases

   - Uncontrolled intercurrent illness

   - Pregnancy or breastfeeding

   - Known HIV positive

   - Known allergy or hypersensitivity to any of the components of the XL184 formulation